Phase 1/2 study of AP26113 in patients (Pts) with advanced malignancies, including anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): Analysis of safety and efficacy at selected phase 2 doses
R. Rosell
Phase 1/2 study of AP26113 in patients (Pts) with advanced malignancies, including anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): Analysis of safety and efficacy at selected phase 2 doses
R. Rosell